Neuren Pharmaceuticals Limited
NURPF
$10.97
-$1.31-10.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 61.55M | 63.29M | 8.02M | 8.00M | 55.07M |
| Total Other Revenue | 1.17M | 1.20M | -- | -- | 5.50K |
| Total Revenue | 62.72M | 64.49M | 8.02M | 8.00M | 55.07M |
| Cost of Revenue | 4.91M | 5.05M | 5.89M | 5.88M | 4.89M |
| Gross Profit | 57.81M | 59.44M | 2.12M | 2.12M | 50.18M |
| SG&A Expenses | 758.20K | 779.60K | 782.20K | 780.60K | 945.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.67M | 5.83M | 6.68M | 6.66M | 5.84M |
| Operating Income | 57.05M | 58.66M | 1.34M | 1.34M | 49.24M |
| Income Before Tax | 55.75M | 57.32M | 3.90M | 3.89M | 50.68M |
| Income Tax Expenses | 12.08M | 12.42M | 1.26M | 1.26M | 15.07M |
| Earnings from Continuing Operations | 43.67M | 44.90M | 2.64M | 2.64M | 35.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.67M | 44.90M | 2.64M | 2.64M | 35.61M |
| EBIT | 57.05M | 58.66M | 1.34M | 1.34M | 49.24M |
| EBITDA | 57.05M | 58.66M | 1.34M | 1.34M | 49.24M |
| EPS Basic | 0.34 | 0.35 | 0.02 | 0.02 | 0.28 |
| Normalized Basic EPS | 0.27 | 0.28 | 0.02 | 0.02 | 0.25 |
| EPS Diluted | 0.33 | 0.34 | 0.02 | 0.02 | 0.27 |
| Normalized Diluted EPS | 0.27 | 0.27 | 0.02 | 0.02 | 0.24 |
| Average Basic Shares Outstanding | 127.86M | 127.86M | 127.67M | 127.67M | 127.80M |
| Average Diluted Shares Outstanding | 130.74M | 130.74M | 130.82M | 130.82M | 131.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |